Running interference: Prospects and obstacles to using small interfering RNAs as small molecule drugs

Derek M Dykxhoorn, Judy Lieberman

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

RNA interference (RNAi) is a well-conserved, ubiquitous, endogenous mechanism that uses small noncoding RNAs to silence gene expression. The endogenous small RNAs, called microRNAs, are processed from hairpin precursors and regulate important genes involved in cell death, differentiation, and development. RNAi also protects the genome from invading genetic elements, encoded by transposons and viruses. When small double-stranded RNAs, called small interfering (si)RNAs, are introduced into cells, they bind to the endogenous RNAi machinery to disrupt the expression of mRNAs containing complementary sequences with high specificity. Any disease-causing gene and any cell type or tissue can potentially be targeted. This technique has been rapidly utilized for gene-function analysis and drug-target discovery and validation. Harnessing RNAi also holds great promise for therapy, although introducing siRNAs into cells in vivo remains an important obstacle. Pilot siRNA clinical studies began just three years after the discovery that RNAi works in mammalian cells. This review discusses recent progress and obstacles to using siRNAs as small molecule drugs.

Original languageEnglish
Pages (from-to)377-402
Number of pages26
JournalAnnual Review of Biomedical Engineering
Volume8
DOIs
StatePublished - Sep 7 2006
Externally publishedYes

Fingerprint

RNA Interference
RNA
Small Interfering RNA
Molecules
Pharmaceutical Preparations
Genes
Small Untranslated RNA
Double-Stranded RNA
Drug Discovery
MicroRNAs
Cell Differentiation
Cell Death
Genome
Viruses
Gene Expression
Messenger RNA
Cell death
Gene expression
Machinery
Cells

Keywords

  • Drug development
  • In vivo delivery
  • RNA interference
  • Therapy

ASJC Scopus subject areas

  • Biophysics
  • Biomedical Engineering

Cite this

Running interference : Prospects and obstacles to using small interfering RNAs as small molecule drugs. / Dykxhoorn, Derek M; Lieberman, Judy.

In: Annual Review of Biomedical Engineering, Vol. 8, 07.09.2006, p. 377-402.

Research output: Contribution to journalArticle

@article{a16b74190b3c4beaa72f455966983772,
title = "Running interference: Prospects and obstacles to using small interfering RNAs as small molecule drugs",
abstract = "RNA interference (RNAi) is a well-conserved, ubiquitous, endogenous mechanism that uses small noncoding RNAs to silence gene expression. The endogenous small RNAs, called microRNAs, are processed from hairpin precursors and regulate important genes involved in cell death, differentiation, and development. RNAi also protects the genome from invading genetic elements, encoded by transposons and viruses. When small double-stranded RNAs, called small interfering (si)RNAs, are introduced into cells, they bind to the endogenous RNAi machinery to disrupt the expression of mRNAs containing complementary sequences with high specificity. Any disease-causing gene and any cell type or tissue can potentially be targeted. This technique has been rapidly utilized for gene-function analysis and drug-target discovery and validation. Harnessing RNAi also holds great promise for therapy, although introducing siRNAs into cells in vivo remains an important obstacle. Pilot siRNA clinical studies began just three years after the discovery that RNAi works in mammalian cells. This review discusses recent progress and obstacles to using siRNAs as small molecule drugs.",
keywords = "Drug development, In vivo delivery, RNA interference, Therapy",
author = "Dykxhoorn, {Derek M} and Judy Lieberman",
year = "2006",
month = "9",
day = "7",
doi = "10.1146/annurev.bioeng.8.061505.095848",
language = "English",
volume = "8",
pages = "377--402",
journal = "Annual Review of Biomedical Engineering",
issn = "1523-9829",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Running interference

T2 - Prospects and obstacles to using small interfering RNAs as small molecule drugs

AU - Dykxhoorn, Derek M

AU - Lieberman, Judy

PY - 2006/9/7

Y1 - 2006/9/7

N2 - RNA interference (RNAi) is a well-conserved, ubiquitous, endogenous mechanism that uses small noncoding RNAs to silence gene expression. The endogenous small RNAs, called microRNAs, are processed from hairpin precursors and regulate important genes involved in cell death, differentiation, and development. RNAi also protects the genome from invading genetic elements, encoded by transposons and viruses. When small double-stranded RNAs, called small interfering (si)RNAs, are introduced into cells, they bind to the endogenous RNAi machinery to disrupt the expression of mRNAs containing complementary sequences with high specificity. Any disease-causing gene and any cell type or tissue can potentially be targeted. This technique has been rapidly utilized for gene-function analysis and drug-target discovery and validation. Harnessing RNAi also holds great promise for therapy, although introducing siRNAs into cells in vivo remains an important obstacle. Pilot siRNA clinical studies began just three years after the discovery that RNAi works in mammalian cells. This review discusses recent progress and obstacles to using siRNAs as small molecule drugs.

AB - RNA interference (RNAi) is a well-conserved, ubiquitous, endogenous mechanism that uses small noncoding RNAs to silence gene expression. The endogenous small RNAs, called microRNAs, are processed from hairpin precursors and regulate important genes involved in cell death, differentiation, and development. RNAi also protects the genome from invading genetic elements, encoded by transposons and viruses. When small double-stranded RNAs, called small interfering (si)RNAs, are introduced into cells, they bind to the endogenous RNAi machinery to disrupt the expression of mRNAs containing complementary sequences with high specificity. Any disease-causing gene and any cell type or tissue can potentially be targeted. This technique has been rapidly utilized for gene-function analysis and drug-target discovery and validation. Harnessing RNAi also holds great promise for therapy, although introducing siRNAs into cells in vivo remains an important obstacle. Pilot siRNA clinical studies began just three years after the discovery that RNAi works in mammalian cells. This review discusses recent progress and obstacles to using siRNAs as small molecule drugs.

KW - Drug development

KW - In vivo delivery

KW - RNA interference

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=33748201603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748201603&partnerID=8YFLogxK

U2 - 10.1146/annurev.bioeng.8.061505.095848

DO - 10.1146/annurev.bioeng.8.061505.095848

M3 - Article

C2 - 16834561

AN - SCOPUS:33748201603

VL - 8

SP - 377

EP - 402

JO - Annual Review of Biomedical Engineering

JF - Annual Review of Biomedical Engineering

SN - 1523-9829

ER -